Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 5/20 | 0.72 |
| ▸ | TP53 | P04637 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | KCNN3 | Q9UGI6 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19700451 | 0.85 | POLB (0.58) | POLBTP53LMNANPSR1HIF1A | |
| SCHEMBL19700453 | 0.83 | KCNN3 (0.51) | POLBTP53LMNANPSR1HIF1A | |
| SCHEMBL19700443 | 0.81 | POLB (0.54) | POLBTP53LMNANPSR1HIF1A | |
| SCHEMBL19690925 | 0.79 | POLB (0.58) | POLBTP53LMNANPSR1HIF1A | |
| SCHEMBL19691003 | 0.76 | POLB (0.57) | POLBTP53LMNANPSR1HIF1A | |
| SCHEMBL19687124 | 0.74 | KCNN2 (0.72) | TP53LMNANPSR1KCNN3ALOX15 | |
| SCHEMBL19686314 | 0.73 | KCNN2 (0.56) | POLBTP53LMNANPSR1KCNN3 | |
| SCHEMBL31127087 | 0.73 | KCNN2 (0.56) | POLBTP53LMNANPSR1KCNN3 | |
| SCHEMBL19686923 | 0.73 | KCNN2 (0.56) | POLBTP53LMNANPSR1KCNN3 | |
| SCHEMBL19686315 | 0.73 | KCNN2 (0.56) | POLBTP53LMNANPSR1KCNN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | POLB 4779/4885TP53 4484/4885LMNA 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.